Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Thomas (RCT) -204% 3.04 [0.13-72.9] death 1/48 0/50 Improvement, RR [CI] Treatment Control Zhao (PSM) 72% 0.28 [0.08-0.93] progression 4/55 12/55 Ried (RCT) 31% 0.69 [0.54-0.89] no recov. 69/162 46/75 Tau​2 = 0.21; I​2 = 43.0% Early treatment 43% 0.57 [0.27-1.23] 74/265 58/180 43% improvement Krishnan 31% 0.69 [0.47-0.92] death 40/79 52/73 Improvement, RR [CI] Treatment Control Zhang (RCT) 50% 0.50 [0.20-1.50] death 6/27 11/29 Patel 29% 0.71 [0.43-1.14] death 22/96 26/80 Kumari (RCT) 36% 0.64 [0.26-1.55] death 7/75 11/75 Darban (RCT) 33% 0.67 [0.14-3.17] progression 2/10 3/10 CT​1 JamaliMog.. (RCT) 0% 1.00 [0.22-4.56] death 3/30 3/30 Gao 86% 0.14 [0.03-0.72] death 1/46 5/30 Hamidi-Ala.. (RCT) 44% 0.56 [0.20-1.51] death 5/40 9/40 CT​1 Al Sulaiman (PSM) 15% 0.85 [0.61-1.12] death 46/142 59/142 Mulhem -32% 1.32 [1.07-1.62] death 157/794 359/2,425 Gadhiya -1% 1.01 [0.48-1.91] death 19/55 36/226 Hakamifard (RCT) 46% 0.54 [0.14-2.08] ICU 3/38 5/34 CT​1 Suna 21% 0.79 [0.44-1.41] death 17/153 24/170 Li (PSM) -11% 1.11 [0.79-1.54] death 7/8 19/24 Vishnuram 54% 0.46 [0.24-0.86] death 164/8,634 10/241 Özgünay 9% 0.91 [0.63-1.30] death 17/32 75/128 Tan 25% 0.75 [0.10-2.98] int./death 1/46 14/115 CT​1 Simsek 44% 0.56 [0.23-1.35] death 6/58 15/81 Tehrani (RCT) 87% 0.13 [0.01-2.25] death 0/18 4/26 Tau​2 = 0.07; I​2 = 55.1% Late treatment 21% 0.79 [0.65-0.96] 523/10,381 740/3,979 21% improvement Behera 18% 0.82 [0.45-1.57] cases case control Improvement, RR [CI] Treatment Control Louca 0% 1.00 [0.97-1.04] cases Holt -3% 1.03 [0.77-1.39] cases 49/1,580 397/13,647 Mohseni -44% 1.44 [1.22-1.71] cases 34/43 307/560 Tau​2 = 0.04; I​2 = 83.4% Prophylaxis -8% 1.08 [0.86-1.35] 83/1,623 704/14,207 -8% improvement All studies 13% 0.87 [0.77-0.99] 680/12,269 1,502/18,366 13% improvement 26 vitamin C COVID-19 studies c19vitaminc.com Dec 3, 2021 1 CT: study uses combined treatmentTau​2 = 0.04; I​2 = 66.1%; Z = 2.07 Effect extraction pre-specified, see appendix Favors vitamin C Favors control
Database of all vitamin C COVID-19 studies. Treatment varies widely across studies and may be high-dose IV vitamin C. Submit updates/corrections.
 
Search:  
Restrict:    All    Early    Late    Prophylaxis
Nov 25
Early Ried et al., Cureus, doi:10.7759/cureus.19902 (Peer Reviewed)
no recov., ↓30.6%, p=0.008
Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial
Details   RCT 237 patients in Turkey, 162 treated with IV vitamin C in addition to HCQ/AZ/zinc/vitamin D used for all patients, showing significantly faster recovery with the addition of IV vitamin C. 97% of patients were vitamin D deficient, and ..
Nov 8
Late Tehrani et al., Urology Journal, doi:10.22037/uj.v18i.6863 (Peer Reviewed)
death, ↓87.1%, p=0.13
An investigation into the Effects of Intravenous Vitamin C on Pulmonary CT Findings and Clinical Outcomes of Patients with COVID 19 Pneumonia A Randomized Clinical Trial
Details   RCT 54 late stage patients, 18 treated with IV vitamin C (2g every 6h for 5 days), showing significant relative improvements in oxygen saturation and respiratory rate.
Oct 25
Late Leal et al., SSRN, doi:10.2139/ssrn.3949424 (Preprint)
death, ↓85.7%, p=0.03
Effect of a Nutritional Support System to Increase Survival and Reduce Mortality in Patients with COVID-19 in Stage III and Comorbidities: A Blinded Randomized Controlled Clinical Trial
Details   80 patient RCT with 40 patients treated with a comprehensive regimen of nutritional support, showing significantly lower mortality with treatment. Treatment contained cholecalciferol, vitamin C, zinc, spirulina maxima, folic acid, glutam..
Oct 20
PrEPPEP Deschasaux-Tanguy et al., European Journal of Public Health, doi:10.1093/eurpub/ckab165.243 (Peer Reviewed) Nutritional risk factors for SARS-CoV-2 infection: prospective study from the NutriNet-Santé cohort
Details   Analysis of 7,766 adults in France, showing higher intakes of vitamin C, folates, vitamin K, dietary fibre, and fruit and vegetables associated with a lower seroprevalence of anti-SARS-CoV-2 antibodies.
Sep 27
Late Simsek et al., Annals of Medical Research, doi:10.5455/annalsmedres.2020.10.1043 (Peer Reviewed)
death, ↓44.1%, p=0.18
Effects of high dose vitamin C administration in Covid-19 patients
Details   Retrospective 139 hospitalized patients in Turkey, 58 treated with high dose vitamin C, showing improved kidney functioning with treatment. Mortality was lower with treatment, but not reaching statistical significance with the small sampl..
Sep 7
Late Xia et al., Aging, doi:10.18632/aging.203503 (Peer Reviewed) High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic: a retrospective cohort study
Details   Retrospective 113 severe and critical patients in China with cardiac injury, 51 treated with high dose vitamin C, showing treatment associated with improvement of myocardial injury.
Aug 17
Late Capone et al., Cureus, doi:10.7759/cureus.9809 (Peer Reviewed) Characterization of Critically Ill COVID-19 Patients at a Brooklyn Safety-Net Hospital
Details   Retrospective 102 ICU patients in the USA, 73 receiving vitamin C and zinc, showing a negative correlation of treatment with mortality, but not reaching statistical significance (p = 0.31).
Aug 4
PrEPPEP Mohseni et al., Nutrition & Food Science, doi:10.1108/NFS-11-2020-0421 (Peer Reviewed)
cases, ↑44.2%, p=0.002
Do body mass index (BMI) and history of nutritional supplementation play a role in the severity of COVID-19? A retrospective study
Details   Retrospective 603 patients in Iran, 34 taking vitamin C supplements, showing increased risk of COVID-19 cases in unadjusted results. IR.SHOUSHTAR.REC.1399.015.
Jul 26
Late Tan et al., QJM, doi:10.1093/qjmed/hcab184 (Peer Reviewed)
int./death, ↓24.5%, p=0.74
Efficacy of diammonium glycyrrhizinate combined with vitamin C for treating hospitalized COVID-19 patients: a retrospective, observational stud
Details   PSM retrospective 207 hospitalized patients in China, 46 treated with diammonium glycyrrhizinate and vitamin C, showing lower risk of ARDS with treatment.
Jul 9
Early Rabail et al., Food Science & Nutrition, doi:10.1002/fsn3.2458 (Peer Reviewed) Nutritional and lifestyle changes required for minimizing the recovery period in home quarantined COVID-19 patients of Punjab, Pakistan
Details   Survey of 80 recovered COVID-19 patients in Pakistan, showing faster recovery with vitamin C, vitamin D, and zinc supplementation.
Jul 6
PrEPPEP Margolin et al., Journal of Evidence-Based Integrative Medicine, doi:10.1177/2515690X211026193 (Peer Reviewed)
cases, ↓94.4%, p=0.003
20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment
Details   Retrospective 113 outpatients, 53 (patient choice) treated with zinc, quercetin, vitamin C/D/E, l-lysine, and Quina, showing lower cases with treatment. Results are subject to selection bias and limited information on the groups is provid..
Jul 4
Late Özgünay et al., The European Research Journal, doi:10.18621/eurj.938778 (Peer Reviewed)
death, ↓9.3%, p=0.69
The use of vitamin C in the intensive care unit during the COVID-19 pandemic
Details   Retrospective 160 ICU patients, 32 with raised neutrophil/lymphocyte ratio treated with vitamin C, showing no significant differences.
Jun 30
Late Vishnuram et al., Indian Journal of Basic and Applied Medical Research, doi:10.36848/IJBAMR/2020/29215.55599 (Peer Reviewed)
death, ↓54.2%, p=0.03
Role of high dose oral liposomal vitamin C in reducing mortality in patients with COVID-19
Details   Retrospective 8,634 hospitalized patients in India, showing lower mortality with high-dose vitamin C in unadjusted results. No group details are provided, the text and table appear to show different results, and some numbers do not match.
Jun 8
Late Li et al., Journal of Pharmacy Practice, doi:10.1177/08971900211015052 (Peer Reviewed)
death, ↑10.5%, p=1.00
Use of Intravenous Vitamin C in Critically Ill Patients With COVID-19 Infection
Details   PSM retrospective 8 ICU patients treated with vitamin C and 24 matched controls, showing no significant difference. Authors note that "it is possible for the delayed timing of IV vitamin C to have blunted the beneficial effects as th..
Jun 1
Review May et al., British Journal of Pharmacology, doi:10.1111/bph.15579 (Review) (Peer Reviewed)
review
Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19
Details   Review of data supporting the use of megadose vitamin C as a treatment for sepsis and COVID-19.
May 11
Late Suna et al., Med. Clin. (Barc.), doi:10.1016/j.medcli.2021.04.010 (Peer Reviewed)
death, ↓21.3%, p=0.52
Effect of high-dose intravenous vitamin C on prognosis in patients with SARS-CoV-2 pneumonia
Details   Retrospective 323 hospitalized patients, 153 treated with vitamin C, showing no significant differences. Patients in each group were in different time periods, with the vitamin C group first. Time based confounding is possible due to impr..
May 3
In Silico Malla et al., bioRxiv, doi:10.1101/2021.05.02.442358 (Preprint) Vitamin C inhibits SARS coronavirus-2 main protease essential for viral replication
Details   In Vitro study showing that vitamin C inhibits SARS-CoV-2 3CLpro. Authors note that the different clinical results may be explained in part by the widely varying dosages used, and they conclude that vitamin C and/or derivatives may become..
Apr 22
Early Zhao et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.638556 (Peer Reviewed)
progression, ↓72.0%, p=0.03
High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study
Details   PSM retrospective 110 patients, 55 treated with high-dose IV vitamin C, showing lower progression to severe disease with treatment. Patients in each group were in different time periods, time based confounding is likely due to SOC improvi..
Apr 14
Late Hakamifard et al., Immunopathologia Persa, doi:10.34172/ipp.2021.xx (Peer Reviewed)
ICU, ↓46.3%, p=0.46
The effect of vitamin E and vitamin C in patients with COVID-19 pneumonia; a randomized controlled clinical trial
Details   RCT with 38 patients treated with vitamin C and vitamin E, and 34 control patients, showing lower ICU admission with treatment, but not statistically significant.
Apr 8
Late Gadhiya et al., BMJ Open, doi:10.1136/bmjopen-2020-042549 (Peer Reviewed)
death, ↑0.7%, p=0.98
Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-network, retrospective cohort study from Pennsylvania state
Details   Retrospective 283 patients in the USA showing higher mortality with all treatments (not statistically significant). Confounding by indication is likely. In the supplementary appendix, authors note that the treatments were usually given fo..
Apr 7
Late Mulhem et al., BMJ Open, doi:10.1136/bmjopen-2020-042042 (Peer Reviewed)
death, ↑32.2%, p=0.01
3219 hospitalised patients with COVID-19 in Southeast Michigan: a retrospective case cohort study
Details   Retrospective database analysis of 3,219 hospitalized patients in the USA. Very different results in the time period analysis (Table S2), and results significantly different to other studies for the same medications (e.g., heparin OR 3.06..
Apr 2
Late Al Sulaiman et al., Research Square, doi:10.21203/rs.3.rs-354711/v1 (Preprint)
death, ↓14.9%, p=0.27
Ascorbic Acid as an Adjunctive Therapy in Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study
Details   Retrospective 158 critically ill patients receiving vitamin C and propensity matched controls, showing mortality OR 0.77 [0.48-1.23], and statistically significantly lower thrombosis, OR 0.42 [0.18-0.94]. 1000mg of vitamin C was given dai..
Mar 30
PrEPPEP Holt et al., medRxiv, doi:10.1101/2021.03.27.21254452 (Preprint)
cases, ↑2.9%, p=0.86
Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK)
Details   Prospective survey-based study with 15,227 people in the UK, showing lower risk of COVID-19 cases with vitamin A, vitamin D, zinc, selenium, probiotics, and inhaled corticosteroids; and higher risk with metformin and vitamin C. Statistica..
Mar 8
Late Hamidi-Alamdari et al., Clinical and Translational Investigation, doi:10.24875/RIC.21000028 (Peer Reviewed)
death, ↓44.4%, p=0.38
Methylene blue for treatment of hospitalized COVID-19 patients: a randomized, controlled, open-label clinical trial, phase 2
Details   RCT 80 hospitalized patients with severe COVID-19, 40 treated with methylene blue + vitamin C + N-acetyl cysteine, showing lower mortality, shorter hospitalization, and significantly improved SpO2 and respiratory distress with treatment. ..
Mar 2
Early Hemilä et al., Research Square, doi:10.21203/rs.3.rs-289381/v1 (Preprint) (meta analysis)
meta-analysis
Vitamin C may increase the recovery rate of outpatient cases of SARS-CoV-2 infection by 70%: reanalysis of the COVID A to Z Randomized Clinical Trial
Details   Reanalysis of Thomas et al. showing that vitamin C increased the recovery rate by 70%, p = 0.025.
Feb 26
Late Gao et al., Aging, doi:10.18632/aging.202557 (Peer Reviewed)
death, ↓86.0%, p=0.04
The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study
Details   Retrospective 76 COVID-19 patients, 46 treated with intravenous high-dose vitamin C, showing lower mortality and improved oxygen requirements with treatment. Dosage was 6g intravenous infusion per 12hr on the first day, and 6g once for th..
Feb 12
Early Thomas et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.0369 (Peer Reviewed)
death, ↑204.2%, p=0.49
Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial
Details   Small 214 low-risk outpatient RCT showing non-statistically significant faster recovery with zinc and with vitamin C. NCT04342728. A secondary analysis concludes that vitamin C increases recovery rate by 71% (p = 0.036) [1]. See also [2].
Feb 9
PrEPPEP Hancock et al., SSRN, doi:10.2139/ssrn.3779211 (Preprint) Case Cluster of RT-PCR COVID-19 Positive Patients with an Unexpected Benign Clinical Course With Vitamin D, Melatonin, Vitamin C, and Viscum Album
Details   Case series of 24 COVID-19 patients (12 confirmed PCR+) treated with vitamin D, vitamin C, and melatonin, showing positive outcomes with no patient having worse than a mild case, including 7 high risk patients.
Feb 1
Levels Muhammad et al., SAGE Open Medicine, doi:10.1177/2050312121991246 (Peer Reviewed) Deficiency of antioxidants and increased oxidative stress in COVID-19 patients: A cross-sectional comparative study in Jigawa, Northwestern Nigeria
Details   Case control study with 50 symptomatic COVID-19 patients and 21 healthy controls in Nigeria, showing that COVID-19 patients had significantly lower levels of selenium and zinc, and vitamins A, C, and E. Control patients were younger than ..
Feb 1
Late Zhao et al., Ann. Palliat. Med., doi:10.21037/apm-20-1387 (Peer Reviewed) Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: a retrospective case series study
Details   Retrospective case study of 12 severe/critical COVID-19 patients finding that high dose IV vitamin C improved inflammatory response, immune and organ function. There was no control group.
Jan 27
Late Xing et al., Journal of Pharmaceutical and Biomedical Analysis, doi:10.1016/j.jpba.2021.113927 (Peer Reviewed) Vitamin C supplementation is necessary for patients with coronavirus disease: An ultra-high-performance liquid chromatography-tandem mass spectrometry finding
Details   Prospective study with 31 COVID-19 patients and 60 controls reporting on a new method to assess plasma vitamin C concentrations. Vitamin C was deficient (11.4µmol/l vs. 52µmol/l for healthy controls), and returned to a normal range (76µmo..
Jan 18
Review Hemilä et al., Frontiers in Medicine, doi:10.3389/fmed.2020.559811 (Review) (Peer Reviewed)
review
Vitamin C and COVID-19
Details   Review of the use of vitamin C for infections and the potential benefit for COVID-19.
Jan 9
Late JamaliMoghadamSiahkali et al., Research Square, doi:10.21203/rs.3.rs-139942/v1 (Preprint)
death, 0.0%, p=1.00
Safety and Effectiveness of High-Dose Vitamin C in Patients with COVID-19; A Randomized Controlled open-label Clinical Trial
Details   Small late stage RCT for the addition of vitamin C to HCQ and lopinavir/ritonavir, with 30 treatment and 30 control patients, finding a significant reduction in temperature and a significant improvement in oxygenation after 3 days in the ..
Dec 15
2020
Late Darban et al., Journal of Cellular & Molecular Anesthesia, doi:10.22037/jcma.v6i2.32182 (Peer Reviewed)
progression, ↓33.3%, p=1.00
Efficacy of High Dose Vitamin C, Melatonin and Zinc in Iranian Patients with Acute Respiratory Syndrome due to Coronavirus Infection: A Pilot Randomized Trial
Details   Small RCT in Iran with 20 ICU patients, 10 treated with high-dose vitamin C, melatonin, and zinc, not showing significant differences. IRCT20151228025732N52.
Dec 7
2020
Review Holford et al., Nutrients, doi:10.3390/nu12123760 (Review) (Peer Reviewed)
review
Vitamin C—An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19
Details   Review of vitamin C use for respiratory infections including COVID-19 and the mechanisms of action. Authors note that evidence to date indicates oral vitamin C (2–8 g/day) may reduce the incidence and duration of respiratory infections, a..
Nov 30
2020
Late Kumari et al., Cureus 12(11): e11779, doi:10.7759/cureus.11779 (Peer Reviewed)
death, ↓36.4%, p=0.45
The Role of Vitamin C as Adjuvant Therapy in COVID-19
Details   RCT 150 hospitalized patients in Pakistan showing 26% faster recovery, p < 0.0001. 36% lower mortality, not statistically significant due to the small number of events. Dosage was 50 mg/kg/day of intravenous vitamin C.
Nov 30
2020
PrEPPEP Louca et al., BMJ Nutrition, Prevention & Health, doi:10.1136/bmjnph-2021-000250 (preprint 11/30/20) (Peer Reviewed)
cases, 0.0%, p=1.00
Modest effects of dietary supplements during the COVID-19 pandemic: insights from 445 850 users of the COVID-19 Symptom Study app
Details   Survey analysis of dietary supplements showing no significant difference in PCR+ cases with vitamin C usage in the UK, however significant reductions were found in the US and Sweden. These results are for PCR+ cases only, they do not refl..
Nov 3
2020
PrEPPEP Behera et al., PLoS ONE, doi:10.1371/journal.pone.0247163 (preprint 11/3) (Peer Reviewed)
cases, ↓18.0%, p=0.58
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study
Details   Retrospective matched case-control prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin. HCQ OR 0.56, ..
Oct 1
2020
Late Patel et al., Chest Infections, doi:10.1016/j.chest.2020.08.322 (Peer Reviewed)
death, ↓29.5%, p=0.18
The significance of oral ascorbic acid in patients with COVID-19
Details   Retrospective 176 hospitalized patients, 96 treated with oral vitamin C (from 500mg to 1500mg daily), showing lower mortality with treatment.
Sep 8
2020
Levels Arvinte et al., Med. Drug Discov, doi:10.1016/j.medidd.2020.100064 (Peer Reviewed) Serum Levels of Vitamin C and Vitamin D in a Cohort of Critically Ill COVID-19 Patients of a North American Community Hospital Intensive Care Unit in May 2020: A Pilot Study
Details   Pilot study with 21 ICU patients finding low serum levels of vitamin C and vitamin D in most patients. Older age and low vitamin C level appeared to be co-dependent risk factors for mortality.
Aug 26
2020
Levels Chiscano-Camón et al., Critical Care, doi:10.1186/s13054-020-03249-y (Peer Reviewed) Vitamin C levels in patients with SARS-CoV-2-associated acute respiratory distress syndrome
Details   Small study of 18 COVID-19 ARDS patients showing that vitamin C levels were very low - 17 patients had undetectable levels and one had a low level (2.4 mg/L).
Aug 10
2020
Late Zhang et al., Annals of Intensive Care, doi:10.1186/s13613-020-00792-3 (Peer Reviewed)
death, ↓50.0%, p=0.20
Pilot Trial of High-dose vitamin C in critically ill COVID-19 patients (preprint 8/10/2020)
Details   Small RCT for high dose vitamin C for ICU patients showing reduced (but not statistically significant) mortality. Dosage was 12g of vitamin C/50ml every 12 hours for 7 days at a rate of 12ml/hour.
Aug 1
2020
Late Hiedra et al., Expert Review of Anti-infective Therapy, doi:10.1080/14787210.2020.1794819 (Peer Reviewed) The use of IV vitamin C for patients with COVID-19: a case series
Details   Case study of 17 patients receiving IV vitamin C for COVID-19, finding a significant decrease in inflammatory markers, including ferritin and D-dimer, and a trend to decreasing FiO2 requirements, after vitamin C administration. There was ..
Jul 25
2020
Review Feyaerts et al., Nutrition, doi:10.1016/j.nut.2020.110948 (Review) (Peer Reviewed)
review
Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19?
Details   Review concluding that there is clear evidence that vitamin C in high doses can reduce interleukin-6 and endothelin-1 mediators. Authors suggest a relatively low dose as prophylaxis, and in cases of severe COVID-19, an (intravenous) high-..
Jul 20
2020
Late Krishnan et al., J Clin Anesth., doi:10.1016/j.jclinane.2020.110005 (Peer Reviewed)
death, ↓30.7%, p=0.04
Clinical comorbidities, characteristics, and outcomes of mechanically ventilated patients in the State of Michigan with SARS-CoV-2 pneumonia
Details   Retrospective 152 mechanically ventilated patients in the USA showing unadjusted lower mortality with vitamin C, vitamin D, HCQ, and zinc treatment, statistically significant only for vitamin C.
Jun 19
2020
Review Biancatelli et al., Frontiers in Immunology, doi:10.3389/fimmu.2020.01451 (Review) (Peer Reviewed)
review
Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19)
Details   Review of the evidence for the use of vitamin C and quercetin both for prophylaxis in high-risk populations and for the treatment of COVID-19 patients.
May 27
2020
In Silico Kumar et al., VirusDisease, doi:10.1007/s13337-020-00643-6 (preprint 5/27) (Peer Reviewed) In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19
Details   In Silico analysis finding that magnesium ascorbate, a form of Vitamin C, was found to be the top compound among 106 nutraceuticals for binding to Mpro of SARS-CoV-2.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit